RegentAtlantic Capital’s PDS Biotechnology PDSB Stock Holding History

RegentAtlantic Capital’s Portfolio PDSB Stock Details PDSB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-15,753	Closed	-$42K	–	457
2019 Q4	$42K	Sell	15,753 -2,492	-14%	-$7.1K	﹤0.01%	460
2019 Q3	$62K	Buy	+18,245	New	+$106K	﹤0.01%	439
2019 Q1	–	Sell	-3,495	Closed	-$22K	–	437
2018 Q4	$22K	Hold	3,495	–	–	﹤0.01%	401
2018 Q3	$57K	Hold	3,495	–	–	﹤0.01%	430
2018 Q2	$72K	Hold	3,495	–	–	0.01%	403
2018 Q1	$82K	Sell	3,495 -1,000	-22%	-$269K	0.01%	406
2017 Q4	$842K	Sell	4,495 -1,125	-20%	-$226K	0.07%	231
2017 Q3	$1.21M	Sell	5,620 -1,125	-17%	-$233K	0.1%	192
2017 Q2	$1.38M	Sell	6,745 -5	-0.1%	-$985	0.13%	173
2017 Q1	$1.23M	Buy	+6,750	New	+$1.34M	0.11%	181
2016 Q4	–	Sell	-1,125	Closed	-$234K	–	392
2016 Q3	$234K	Buy	+1,125	New	+$223K	0.02%	353

Other funds holding PDSB

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RegentAtlantic Capital's PDSB Position: Q1 2020 in Review

RegentAtlantic Capital sold out of PDS Biotechnology (PDSB) in Q1 2020, closing a stake of 15,753 shares — an estimated $42K sold.

RegentAtlantic Capital first reported a position in PDSB in Q3 2016 and held it in 11 quarters. The position peaked at $1.38M in Q2 2017. 28 funds tracked by Wall St. Rank hold PDSB as of Q1 2020.

RegentAtlantic Capital reported no remaining PDS Biotechnology position as of Q1 2020 after selling out during the quarter.
RegentAtlantic Capital sold 15,753 PDS Biotechnology shares in Q1 2020, an estimated $42K.
RegentAtlantic Capital first reported a position in PDS Biotechnology in Q3 2016 and held it in 11 quarters.
RegentAtlantic Capital's PDS Biotechnology position peaked at $1.38M in Q2 2017.
28 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2020.

Based on RegentAtlantic Capital's 13F filing for Q1 2020, filed 14 May 2020.